Tafamidis meglumine

Tafamidis meglumine (Vyndaqel, Fx-1006A) stabilizes the tetrameric structure of transthyretin (TTR) by binding to thyroxine-binding sites. Tafamidis meglumine treats transthyretin familial amyloid polyneuropathies (TTR-FAP), a condition characterized by neurological damage from TTR amyloidosis, by preventing the misfolding and aggregation of transthyretin (TTR) into amyloid fibrils.

Price Not Available 100mg Tafamidis meglumine Supplier Page

Trivial name	Vyndaqel, Fx-1006A
Catalog Number	E4852
Molecular Formula	C18H13N7S
CAS#	951395-08-7
Inchi	InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3
Inchi Key	BCZUAADEACICHN-UHFFFAOYSA-N
SMILES	CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2
Size	100mg
Supplier Page	http://www.selleckchem.com/products/tafamidis-meglumine.html
Additional Information	https://file.selleck.cn/downloads/struct/E4852-Tafamidis-meglumine-chemical-structure.png